|
ATE400252T1
(de)
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
|
US6440959B1
(en)
|
1999-04-21 |
2002-08-27 |
Hoffman-La Roche Inc. |
Pyrazolobenzodiazepines
|
|
AR033651A1
(es)
*
|
1999-10-01 |
2004-01-07 |
Hoffmann La Roche |
Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
|
|
US6313143B1
(en)
*
|
1999-12-16 |
2001-11-06 |
Hoffmann-La Roche Inc. |
Substituted pyrroles
|
|
WO2001087368A1
(en)
*
|
2000-05-16 |
2001-11-22 |
Ortho-Mcneil Pharmaceutical, Inc. |
Process for coating medical devices using super-critical carbon dioxide
|
|
US6469179B1
(en)
|
2000-10-03 |
2002-10-22 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
|
US6482847B2
(en)
*
|
2000-10-03 |
2002-11-19 |
Hoffmann-La Roche Inc. |
Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
|
|
US6884436B2
(en)
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
|
US6951656B2
(en)
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US8067032B2
(en)
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
|
US7193084B2
(en)
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
|
US6977085B2
(en)
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
|
US7037528B2
(en)
|
2000-12-22 |
2006-05-02 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
|
US6548531B2
(en)
|
2001-02-09 |
2003-04-15 |
Hoffmann-La Roche Inc. |
Method for cancer therapy
|
|
US6716845B2
(en)
|
2001-03-30 |
2004-04-06 |
Hoffmann-La Roche Inc. |
Barbituric acid derivatives
|
|
WO2003013478A2
(en)
*
|
2001-05-30 |
2003-02-20 |
Csir |
Method of encapsulating an active substance
|
|
US20030044514A1
(en)
*
|
2001-06-13 |
2003-03-06 |
Richard Robert E. |
Using supercritical fluids to infuse therapeutic on a medical device
|
|
WO2002102373A1
(en)
*
|
2001-06-15 |
2002-12-27 |
F. Hoffmann-La Roche Ag |
Method for administration of cancer therapeutic
|
|
PT1404300E
(pt)
|
2001-06-22 |
2009-11-09 |
Bend Res Inc |
Composições farmacêuticas de dispersões de fármacos e polímeros neutros
|
|
BR0210530A
(pt)
|
2001-06-22 |
2004-06-22 |
Pfizer Prod Inc |
Composições farmacêuticas de drogas e poìimeros acìdicos neutralizados
|
|
US20060003012A9
(en)
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
|
BR0212833A
(pt)
|
2001-09-26 |
2004-10-13 |
Baxter Int |
Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
|
|
US7112340B2
(en)
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
|
US20030139373A1
(en)
*
|
2001-11-20 |
2003-07-24 |
Breimer Lars Holger |
Method for cancer therapy
|
|
ES2878403T3
(es)
|
2002-02-01 |
2021-11-18 |
Bend Res Inc |
Método para preparar dispersiones de fármacos amorfas sólidas homogéneas secadas mediante pulverización utilizando aparatos de secado por pulverización modificados
|
|
BR0313428A
(pt)
|
2002-08-12 |
2005-06-28 |
Pfizer Prod Inc |
Composições farmacêuticas de drogas semi-ordenados e polìmeros
|
|
DE10351087A1
(de)
*
|
2003-10-31 |
2005-05-25 |
Bayer Technology Services Gmbh |
Feste Wirkstoff-Formulierung
|
|
KR101118930B1
(ko)
|
2003-11-14 |
2012-03-14 |
아지노모토 가부시키가이샤 |
페닐알라닌 유도체의 고체 분산체 또는 고체 분산체 의약제제
|
|
EP1683525B1
(en)
*
|
2003-11-14 |
2017-05-17 |
EA Pharma Co., Ltd. |
Sustained-release phenylalanine derivative preparation for oral administration
|
|
US20070191404A1
(en)
*
|
2004-04-01 |
2007-08-16 |
Pierre Bartsch |
Pharmaceutical compositions of pyrimidine-2,4,6-triones
|
|
AR049915A1
(es)
*
|
2004-06-14 |
2006-09-13 |
Anacor Pharmaceuticals Inc |
Compuestos con contenido de boro y metodos de uso de los mismos
|
|
WO2006062980A2
(en)
*
|
2004-12-07 |
2006-06-15 |
Nektar Therapeutics |
Stable non-crystalline formulation comprising tiagabine
|
|
EP1839650A1
(en)
*
|
2004-12-28 |
2007-10-03 |
Eisai R&D Management Co., Ltd. |
Quick disintegration tablet and method of producing the same
|
|
CN103102303B
(zh)
|
2004-12-31 |
2015-10-28 |
雷迪博士实验室有限公司 |
作为cetp抑制剂的苄胺衍生物
|
|
US8604055B2
(en)
|
2004-12-31 |
2013-12-10 |
Dr. Reddy's Laboratories Ltd. |
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
|
|
TW200633723A
(en)
*
|
2005-01-27 |
2006-10-01 |
Corium Int Inc |
Hydrophilic biocompatible adhesive formulations and uses
|
|
EP1690528A1
(de)
*
|
2005-02-11 |
2006-08-16 |
Abbott GmbH & Co. KG |
Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
|
|
EP1885338A1
(en)
*
|
2005-05-19 |
2008-02-13 |
Pfizer, Inc. |
Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
|
|
EP1767194A1
(de)
*
|
2005-06-09 |
2007-03-28 |
Helm AG |
Verfahren zur Herstellung von Adsorbaten des Drospirenons
|
|
NZ565255A
(en)
*
|
2005-06-22 |
2010-04-30 |
Plexxikon Inc |
Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
|
|
US20080031944A1
(en)
*
|
2006-08-04 |
2008-02-07 |
Cima Labs Inc. |
Stabilization of lorazepam
|
|
CA2660374A1
(en)
*
|
2006-08-10 |
2008-02-14 |
Cipla Limited |
Antiretroviral solid oral composition
|
|
US20080107725A1
(en)
*
|
2006-10-13 |
2008-05-08 |
Albano Antonio A |
Pharmaceutical Solid Dosage Forms Comprising Amorphous Compounds Micro-Embedded in Ionic Water-Insoluble Polymers
|
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
|
WO2008079909A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
|
PE20081581A1
(es)
*
|
2006-12-21 |
2008-11-12 |
Plexxikon Inc |
COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
|
|
WO2008081829A1
(ja)
|
2006-12-27 |
2008-07-10 |
Astellas Pharma Inc. |
難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe
|
|
CN101702878B
(zh)
*
|
2007-05-11 |
2012-11-28 |
弗·哈夫曼-拉罗切有限公司 |
可溶性差的药物的药物组合物
|
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
|
EP1997479A1
(en)
*
|
2007-05-31 |
2008-12-03 |
Helm AG |
Stabilized amorphous candesartan cilexetil compositions for oral administration
|
|
MX2010000617A
(es)
|
2007-07-17 |
2010-05-17 |
Plexxikon Inc |
Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
|
|
WO2009052391A1
(en)
*
|
2007-10-19 |
2009-04-23 |
Purdue Research Foundation |
Solid formulations of crystalline compounds
|
|
US8632805B2
(en)
*
|
2008-06-20 |
2014-01-21 |
Mutual Pharmaceutical Company, Inc. |
Controlled-release formulations, method of manufacture, and use thereof
|
|
US7794750B2
(en)
*
|
2008-06-20 |
2010-09-14 |
Mutual Pharmaceutical Company, Inc. |
Controlled-release formulations, method of manufacture, and use thereof
|
|
WO2010044842A1
(en)
*
|
2008-10-16 |
2010-04-22 |
University Of Tennessee Research Foundation |
Tamper resistant oral dosage forms containing an embolizing agent
|
|
KR20100073454A
(ko)
*
|
2008-12-23 |
2010-07-01 |
국립암센터 |
트란스글루타미나제 억제제로 사용되는 신규한 피라졸로디아제핀계 화합물, 이의 제조방법 및 이를 포함하는 조성물
|
|
AU2010232670B2
(en)
|
2009-04-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
|
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
|
MA33975B1
(fr)
|
2009-11-06 |
2013-02-01 |
Plexxikon Inc |
Composés et méthodes de modulation des kinases et leurs indications d'emploi
|
|
CN103153306A
(zh)
*
|
2010-05-31 |
2013-06-12 |
安斯泰来制药有限公司 |
三唑化合物的固体分散体
|
|
HUE040136T2
(hu)
|
2011-02-07 |
2019-02-28 |
Plexxikon Inc |
Vegyületek és eljárások kináz modulációra és azok indikációi
|
|
BR112013021030A2
(pt)
|
2011-02-17 |
2016-10-11 |
Hoffmann La Roche |
processo para cristalização controlada de um ingrediente farmacêutico ativo a partir de estado líquido super-refrigerado por extrusão por fusão a quente
|
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
|
DK3135656T3
(en)
|
2011-06-20 |
2019-04-23 |
H Lundbeck As |
DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF schizophrenia
|
|
KR101774223B1
(ko)
|
2011-08-18 |
2017-09-12 |
닥터 레디스 레보러터리즈 리미티드 |
콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
|
|
WO2013037396A1
(en)
*
|
2011-09-12 |
2013-03-21 |
Bioneer A/S |
Solution of polymer in api for a solid dosage form
|
|
AU2012313971B2
(en)
|
2011-09-27 |
2016-09-29 |
Dr. Reddy's Laboratories, Ltd. |
5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis
|
|
SG11201401459YA
(en)
|
2011-10-14 |
2014-07-30 |
Array Biopharma Inc |
Solid dispersions of a erb2 (her2) inhibitor
|
|
EP3400943B1
(en)
*
|
2012-03-23 |
2020-12-02 |
Array Biopharma, Inc. |
Compounds for use in the treatment of brain metastases in a patient with erbb2+ breast cancer
|
|
US20140128431A1
(en)
|
2012-04-03 |
2014-05-08 |
Hoffmann-Laroche Inc. |
Pharmaceutical composition with improved bioavailability, safety and tolerability
|
|
EP2649989B1
(en)
|
2012-04-13 |
2017-10-18 |
King Saud University |
Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
|
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
|
JO3339B1
(ar)
*
|
2012-09-11 |
2019-03-13 |
Shanghai Inst Pharmaceutical Ind |
شكل مستقر غير متبلور من الأغوميلاتين وعملية تحضيره والتركيبات الدوائية التي تحتوي عليه
|
|
HK1214160A1
(zh)
|
2012-11-19 |
2016-07-22 |
雷迪博士实验室有限公司 |
Cetp抑制剂的药物组合物
|
|
CA2895534C
(en)
*
|
2012-12-20 |
2019-10-22 |
Kashiv Pharma, Llc |
Orally disintegrating tablet formulation for enhanced bioavailability
|
|
SG11201504499VA
(en)
|
2013-01-22 |
2015-08-28 |
Hoffmann La Roche |
Pharmaceutical composition with improved bioavailability
|
|
TWI615157B
(zh)
|
2013-02-06 |
2018-02-21 |
大塚製藥股份有限公司 |
包括不定形西洛他唑的固體分散劑
|
|
WO2015038376A1
(en)
*
|
2013-09-11 |
2015-03-19 |
3M Innovative Properties Company |
Coating compositions, dental structures thereof and methods for generating contrast
|
|
EP3076951B1
(en)
*
|
2013-12-05 |
2020-09-30 |
Celal Albayrak |
Process for the production of drug formulations for oral administration
|
|
PT107846B
(pt)
*
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
RU2017144222A
(ru)
*
|
2015-05-29 |
2019-07-02 |
Сан Фармасьютикал Индастриз Лимитед |
Фармацевтическая пероральная композиция изотретиноина
|
|
RS66947B1
(sr)
|
2016-12-13 |
2025-07-31 |
Transthera Sciences Nanjing Inc |
Jedinjenje inhibitora više kinaza, i njegova kristalna forma i upotreba
|
|
WO2018201016A1
(en)
|
2017-04-28 |
2018-11-01 |
Cascadian Therapeutics, Inc. |
Treatment of her2 positive cancers
|
|
KR102082775B1
(ko)
*
|
2017-05-02 |
2020-02-28 |
주식회사 삼양바이오팜 |
수용해도 및 생체이용율이 개선된 조성물
|
|
RU2725879C2
(ru)
*
|
2018-07-26 |
2020-07-07 |
Федеральное государственное бюджетное образовательное учреждение высшего образования "Казанский Государственный медицинский университет" Министерства здравоохранения Российской Федерации |
Интерполимерный носитель для пероральных систем контролируемой доставки активных фармацевтических ингредиентов
|
|
WO2020114853A1
(en)
|
2018-12-03 |
2020-06-11 |
H. Lundbeck A/S |
Prodrugs of 4-((1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1/r,3s)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1h-inden-1-yl)-2,2-dimethy-1-(methyl-d3)piperazine
|
|
EP4093379A1
(en)
|
2020-01-24 |
2022-11-30 |
Nanocopoeia LLC |
Amorphous solid dispersions of dasatinib and uses thereof
|
|
CA3168680A1
(en)
|
2020-01-31 |
2021-08-05 |
Nanocopoeia, Llc |
Amorphous nilotinib microparticles and uses thereof
|
|
JP7705715B2
(ja)
|
2020-03-03 |
2025-07-10 |
デクセリアルズ株式会社 |
画像表示装置の製造方法
|
|
EP4142699A1
(en)
|
2020-04-30 |
2023-03-08 |
Nanocopoeia LLC |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
|
|
US11980619B2
(en)
|
2021-07-28 |
2024-05-14 |
Nanocopoeia, Llc |
Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
|